Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT for Refractory Gut GVHD
NCT03549676Phase 1Unknown
- Start
- Jul 2019
- Primary completion
- May 2020
- Modality
- Live Biotherapeutic Products
01
Overview
Phase 1, open-label, single-arm trial of fecal microbiome transplant in graft-versus-host disease (GVHD). Primary endpoints: Efficacy of FMT in the treatment of refractory GVHD on day 7 and Efficacy of FMT in the treatment of refractory GVHD on day 28. Status: unknown.
02
Drugs
fecal microbiome transplant
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT03549676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03549676.